Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
about
Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort studyDouble or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallelHow we treat bleeding associated with direct oral anticoagulantsNovel oral anticoagulants and the 73rd anniversary of historical warfarinThe case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratioHow to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationOral direct thrombin inhibition: a double-edged sword?Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsDabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional ExperienceStroke prevention in older adults with atrial fibrillationSafety of new oral anticoagulant drugs: a perspectiveMinimizing bleeding risk in patients receiving direct oral anticoagulants for stroke preventionRisk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesEfficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-AnalysisAnticoagulation in atrial fibrillationWarfarin Pharmacogenetics: New Life for an Old DrugAtrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes.Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt).Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFReal Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.Effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with atrial fibrillation: A single-center observational studyEffectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyDirect oral anticoagulants and digestive bleeding: therapeutic management and preventive measures.Dabigatran in secondary stroke prevention: clinical experience with 106 patients.Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeManaging target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden.Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials.Enhanced elimination of dabigatran through extracorporeal methods.Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.
P2860
Q24658646-94BCA452-5AC1-41A9-B562-9319AA149142Q26741058-745F7571-5BFE-44E6-9495-2F1B5EACC5EBQ26748343-543E3B87-9306-43D9-BF0A-0CFFB818943FQ26771544-EE8AA354-695B-4170-A66D-0432C9DB21B9Q26776239-7DE6C5A6-2BE7-4B18-924F-4EB6661EA617Q26776413-217B7156-C584-4284-8529-CDED4831BAF2Q26780154-C8DBDF21-6325-460A-8259-0D16BFDD6257Q26781181-45F151C5-B7B3-4C69-9E76-5EBC79FC1980Q26783457-EC319E55-8988-44A0-9883-1052E388DD11Q26830227-3275FC31-06AE-45F0-A75B-3C50161B816DQ27016072-0C99FFCE-F875-48B4-9F1C-78217EB06DEAQ28069809-7F45CA63-0D51-4330-A8EF-07912FCF37E8Q28078747-F912331D-AC3D-4D89-85F7-3F90F42381B2Q28085676-C331E2C5-BC34-4644-B905-C54EF8838D66Q28315636-2BED6104-B0DD-423E-9AEB-3B6991C0972BQ28468726-8BAE4611-DEA3-4A49-993F-412DC447BA94Q30234626-D39564DA-16F7-4DF2-9BBE-8B1B08044AE5Q30853679-71F08A26-BDEA-4F48-9A4B-4ED849B4683CQ30858079-700162D0-4433-49CA-9F3A-E592C45CA126Q30979197-9D9FE1BE-A6F8-4313-8820-6E6A4C043746Q30994474-18463A4E-6B5F-4124-8093-F51324C7BBA7Q31054764-91868440-1436-4843-B50F-C9CBBD9C53C4Q31098679-0C00BF58-415C-4575-9F20-77647762E619Q31131255-C1AD88E8-7545-485E-A13F-E12E48F61FCEQ33552976-5D268FFC-E9C1-4028-9634-A233B7B9967EQ33647367-154A99FD-6887-46B1-B9EB-1FF369235A1FQ33656869-183765E8-F250-4559-A127-2C49291EC639Q34009254-E3B5DBF7-A309-4D3E-A119-37A375817C36Q34091490-2E16C7E5-85CE-4B14-95B2-191851C3EF8EQ34109813-CA88B3E5-A612-4973-8148-D8CAF0466507Q34469002-A9CE91B3-A77A-4A67-9483-596818CE7CD1Q34571082-89FDDE55-6F4C-4E52-A0DF-E289B3497566Q34667503-D04E5192-550E-4B09-8999-20E20F036F74Q34694471-60E1792B-C9EA-4CED-AF52-235680981A3EQ34725585-E297A721-C0A5-4E6D-B1F7-1837DB6957BDQ34787240-976F911C-C651-4F20-9576-8E79CB614EE6Q35062047-84E1CBA3-DEB6-4FCE-AAA6-0ABB4C49B04AQ35160888-377E4AF3-15DE-4604-BDBA-2430FBDEF8F0Q35210137-2C013ADD-4E6D-492C-B099-72E2C626A01BQ35798597-DD71CDB4-A982-4610-8EF3-4C928160233E
P2860
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Efficacy and safety of dabigat ...... ctive nationwide cohort study.
@en
Efficacy and safety of dabigat ...... ctive nationwide cohort study.
@nl
type
label
Efficacy and safety of dabigat ...... ctive nationwide cohort study.
@en
Efficacy and safety of dabigat ...... ctive nationwide cohort study.
@nl
prefLabel
Efficacy and safety of dabigat ...... ctive nationwide cohort study.
@en
Efficacy and safety of dabigat ...... ctive nationwide cohort study.
@nl
P2093
P50
P1476
Efficacy and safety of dabigat ...... ctive nationwide cohort study.
@en
P2093
Karen Margrete Due
Lars Hvilsted Rasmussen
Mary Rosenzweig
Torbjörn Callréus
P304
P356
10.1016/J.JACC.2013.03.020
P407
P577
2013-04-03T00:00:00Z